



# Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins.

Anne Clavreul, Amandine Etcheverry, Clément Téaud, Audrey Rousseau,  
Tony Avril, Cécile Henry, Jean Mosser, Philippe Menei

## ► To cite this version:

Anne Clavreul, Amandine Etcheverry, Clément Téaud, Audrey Rousseau, Tony Avril, et al.. Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins.. Journal of Neuro-Oncology, 2015, 122 (1), pp.1-10. 10.1007/s11060-014-1683-z . hal-01117114

HAL Id: hal-01117114

<https://univ-rennes.hal.science/hal-01117114>

Submitted on 3 Jun 2015

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties  
in histologically normal surgical margins**

Anne Clavreul<sup>1,2,3</sup>, Amandine Etcheverry<sup>4,5,6</sup>, Clément Téaud<sup>1,2</sup>, Audrey Rousseau<sup>1,2,7</sup>, Tony Avril<sup>8</sup>, Cécile Henry<sup>9</sup>, Jean Mosser<sup>4,5,6,10</sup>, Philippe Menei<sup>1,2,3</sup>

<sup>1</sup>LUNAM, Université d'Angers, 49035 Angers, France

<sup>2</sup>INSERM U1066, Micro et Nanomédecines Biomimétiques (MINT), 49933 Angers, France

<sup>3</sup>Département de Neurochirurgie, CHU, 49933 Angers, France

<sup>4</sup>CNRS, UMR 6290, Institut de Génétique et Développement de Rennes (IGdR), 35043 Rennes, France

<sup>5</sup>Université Rennes1, UEB, UMS 3480 Biosit, Faculté de Médecine, 35043 Rennes, France

<sup>6</sup>CHU Rennes, Service de Génétique Moléculaire et Génomique, 35033 Rennes, France

<sup>7</sup>Laboratoire Pathologie Cellulaire et Tissulaire, CHU, 49933 Angers, France

<sup>8</sup>Centre Régional de Lutte Contre le Cancer Eugène Marquis, 35000 Rennes, France

<sup>9</sup>Centre Régional de Lutte Contre le Cancer Paul Papin, INSERM U892, 49000 Angers, France

<sup>10</sup>Plate-forme Génomique Santé Biosit, Université Rennes1, 35043 Rennes, France

**Contact:** Anne Clavreul, INSERM U1066, 49100 Angers, France.

Phone: +33 244 688548; Fax: +33 244 688546; E-mail: [anne.clavreul@univ-angers.fr](mailto:anne.clavreul@univ-angers.fr)

**Funding:** This work was supported by the Pays de la Loire and Bretagne regions and Ligue contre le cancer-49-Comité de Maine-et-Loire.

**Abbreviations:** **CAF**s, cancer-associated fibroblasts; **CM**, conditioned medium, **DMEM-HG**, Dulbecco's modified Eagles' medium-high glucose; **EBM-2**, endothelial basal medium-2; **EGM-2**, endothelial cell growth medium-2; **FCA**, absolute fold-change; **FCS**, foetal calf serum; **GASCs**, glioblastoma-associated stromal cells; **GB**, glioblastoma; **HABS**, human AB serum; **HUVECs**, human umbilical vein endothelial cells; **PDGFR $\beta$** , platelet derived growth factor receptor-beta;  **$\alpha$ SMA**, alpha smooth muscle actin

## **Abstract**

Glioblastoma (GB) is a highly infiltrative tumor recurring within a few centimeters of the resection cavity in 90% of cases, even in cases of complete tumor resection and adjuvant chemo/radiotherapy. We recently isolated GB-associated stromal cells (GASCs) from the GB peritumoral zone, with phenotypic and functional properties similar to those of the cancer-associated fibroblasts (CAFs) present in the stroma of carcinomas. In particular, GASCs promote blood vessel development and have tumor-promoting effects on glioma cells *in vitro* and *in vivo*. In this study, we characterized these cells further, by analyzing the transcriptome and methylome of 14 GASC and five control stromal cell preparations derived from non-GB peripheral brain tissues. We identified two subtypes of GASCs in surgical margins in GB patients: GASC-A and GASC-B. GASC-B promoted the development of tumors and endothelium, whereas GASC-A did not. A difference in DNA methylation may underlie these two subtypes. We identified various proteins as being produced in the procarcinogenic GASC-B. Some of these proteins may serve as prognostic factors for GB and/or targets for anti-glioma treatment. In conclusion, in this era of personalized therapy, the status of GASCs in GB-free surgical margins should be taken into account, to improve treatment and the prevention of recurrence.

## **Keywords**

Translational study, glioblastoma, peritumoral brain zone, cancer-associated fibroblasts

## **Introduction**

Glioblastoma (GB) has a poor prognosis, despite aggressive treatment by surgery, radiotherapy and chemotherapy [1, 2]. Even in cases of complete resection of the gadolinium-enhanced portion of the GB, 85% of recurrences occur in the resection margin [3]. Recurrence is thought to result from the proliferation of residual unresected tumor cells. Such cells have been isolated and shown to display alterations different from those of cells isolated from the corresponding tumor mass [4, 5]. In addition to containing unresected tumor cells, the tumor microenvironment may play a determinant role in local recurrence. It contains a number of different cellular elements, including inflammatory cells, endothelial cells and fibroblasts. Cancer-associated fibroblasts (CAFs), commonly referred to as myofibroblasts, constitute a significant component of the tumor stroma of carcinomas [6]. These cells have been shown to play an active role in reciprocal communication with tumor cells, thereby accelerating tumor growth and progression. We isolated a population of such stromal cells from the histologically normal surgical margins of GB by computer-guided stereotaxic biopsy and primary culture. We named these cells GB-associated stromal cells (GASCs). These cells were mostly located close to blood vessels. They were diploid, did not display the genomic alterations typical of GB cells and expressed markers associated with CAFs, including alpha-smooth muscle actin ( $\alpha$ SMA), platelet-derived growth factor receptor-beta (PDGFR $\beta$ /CD140b) and FSP1 [7, 8]. GASCs were also found to have tumor-promoting effects on glioma cells *in vitro* and *in vivo* and to have angiogenic properties [7, 8]. All these data suggest that GASCs may be a component of the vascular niche in surgical margins, establishing a permissive environment for angiogenesis and the proliferation of recurrence-initiating cells.

In this study, we investigated the transcriptomes and methylomes of 14 GASC and five control stromal cell preparations derived from non-GB peripheral brain tissues. We identified two types of GASCs in surgical margins in GB patients: one subtype with, and the other without tumor-promoting and angiogenic properties.

## **Materials and Methods**

### **Establishment of primary GASCs and control stromal cells**

The entire project was approved by the local institutional review board (CPP Ouest II) and the *Direction générale de la santé* (DGS). All patients undergoing surgery signed an informed consent form for participation in this study. Peripheral brain biopsy specimens were obtained from 14 patients with *de novo* GB and from five non-GB patients, for the propagation of primary GASCs and control stromal cells, respectively (Supplementary Table 1). Briefly, biopsy specimens were minced and mechanically dissociated in Dulbecco's modified Eagles'

medium-high glucose (DMEM-HG) (Lonza, Verviers, Belgium), as previously described [8]. The resulting suspension was used to seed T80 flasks (Nunc, Dominique Dutsher, Brumath, France) containing DMEM supplemented with 10% human AB serum (HABS) (EFS, Lyon, France) and 1% antibiotics (Sigma-Aldrich, Saint Quentin Fallavier, France), which was then incubated at 37°C in a humidified incubator, under an atmosphere containing 5% CO<sub>2</sub>. After several days, the outgrowth of spindle-shaped cells was observed. Experiments were performed with cells between passages 5 and 7. GASCs and control stromal cells were diploid, negative for the endothelial marker CD31 and the hematopoietic lineage markers (CD45, CD34), but positive for CAF-associated biomarkers, including αSMA, PDGFRβ and FSP1 (S100A4) (data not shown).

### **Cell-line culture**

The aneuploid non-tumorigenic (A172) and diploid tumorigenic (U87MG) GB cell lines were provided by ATCC (LGC Promochem, Molsheim, France). They were maintained in the same medium as GASCs and control stromal cells at 37°C, under an atmosphere containing 5% CO<sub>2</sub>, until they reached 80 to 90% confluence.

Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza. Cells were cultured according to the supplier's instructions, in endothelial cell growth medium-2 (EGM-2), corresponding to endothelial basal medium-2 (EBM-2) containing the supplements and growth factors of the EGM-2 SingleQuot kit (Lonza), in a humidified chamber at 37°C, under an atmosphere containing 5% CO<sub>2</sub>.

### **Gene expression profiling and methylation analysis**

Total RNA and DNA were extracted with NucleoSpin RNAII and NucleoSpin Tissue kits, respectively (Macherey-Nagel, Hoerdt, France). Gene expression profiling was performed with the Agilent Whole Human Genome 8 × 60K Microarray Kit (Agilent Technologies, Santa Clara, USA) and DNA methylation profiling was performed with the Infinium Human Methylation 450 beadchip (Illumina Inc., San Diego, USA). For a detailed description of the gene expression profiling and methylation analysis, see Supplementary Methods.

### **Phenotypic analysis by flow cytometry**

The following primary antibodies were used for flow cytometry: anti-CD146/MCAM, anti- PDGFRβ/CD140b, anti-ICAM1, anti-EGFR and isotype control antibodies from BD Biosciences (Le Pont de Claix, France); anti-αSMA, anti-nestin and anti-NG2/CSPG4 antibodies from R&D Systems (Lille, France); and anti-S100A4/FSP1, anti-THBS1 and anti-VASP antibodies from Abcam (Paris, France). The staining protocol used was as previously described [7, 8]. The stained cells were analyzed in a FACScan flow cytometer with CellQuest Software (BD Biosciences).

### **Preparation of conditioned media**

GASCs were grown to 70% to 80% confluence in DMEM-HG containing 10% HABS and 1% antibiotics. The medium was replaced with EBM-2 or DMEM-HG supplemented with 0.1% HSA and 0.2% antibiotics and the cells were cultured for a further 24 h. The resulting conditioned medium (CM) was centrifuged and stored at -20°C for subsequent use.

### **Functional analyses on GB cell lines**

#### ***Invasion assay***

Transwell inserts (Millicell® cell culture inserts, 8 µm pore size) with a thin layer of Matrigel basement membrane matrix (BD Biosciences) were used to assess A172 cell invasion in response to factors secreted by GASCs. Briefly, A172 cells ( $5 \times 10^4$  cells) were added to the upper chamber, and 500 µl of negative control medium (DMEM-HG supplemented with 0.1% HSA and 0.2% antibiotics), positive control medium (10% HABS) or GASC-CM was added to the bottom chamber. After 6 h, the cells that had migrated to the underside of the insert membrane After 6 h, the cells that had invaded to the underside of the insert membrane were stained with hematoxylin and counted with a computerized image-analysis system (MetaView, Roper Scientific, Evry, France). Six fields per insert, at a magnification of  $\times 200$ , were used to count the cells that had invaded. Cell invasion values are expressed as means  $\pm$  SEM of the percentage of cells invading in the different conditions.

#### ***In vitro proliferation assay***

We assessed the ability of GASCs to affect the proliferation of GB cells, using the aneuploid glioma cell line A172, to make it possible to distinguish between tumor cells and diploid GASCs. GASCs were used to seed six-well plates, at a density of  $96 \times 10^3$  cells per well, and were cultured in DMEM supplemented with 10% HABS and 1% antibiotics for 24 h. We then added  $96 \times 10^3$  A172 cells per well. The cells were cocultured for three days and then harvested. We used Vindelov's protocol to stain chromosomal DNA [9] and the cells were analyzed by flow cytometry with a FACScan flow cytometer (BD Biosciences). We calculated the DNA index (DI) and the percentages of the cell populations in each culture, as determined on the basis of their DNA content, with Modfit version 5.2 software (Verity Software House, Topsham, Maine), as previously described [10]. Cell-cycle analysis was carried out on the aneuploid A172 cells, and the proliferation index (PI) of these cells was evaluated as the percentage of cells in S+G2M phase.

#### ***In vivo implantation***

Female Swiss nude mice (8-10 weeks old) were obtained from Charles River Laboratories (L'Arbresle, France).

The protocol was approved by the Committee on the Ethics of Animal Experiments of the "Pays de la Loire" (Permit Number: CEEA.2010.45). U87MG cells were subcutaneously injected into the right flank alone ( $0.5 \times 10^6$  cells,  $n = 7$ ) or together with  $0.5 \times 10^6$  GASCs [GASC-A (GASC-31);  $n = 5$  or GASC-B (GASC-3);  $n = 4$ ]. Tumor volume within the flank was determined by direct measurement with a digital caliper, twice weekly, and was calculated as follows:  $0.5 \times (\text{largest diameter}) \times (\text{smallest diameter})^2$ .

### **Functional analyses on HUVECs**

#### ***Migration assay***

Transwell inserts (Millicell<sup>®</sup> cell culture inserts, 8  $\mu\text{m}$  pore size, Millipore) were used to assess the migration of HUVECs in response to factors secreted by GASCs. For these experiments, HUVECs ( $2.5 \times 10^4$  cells) were added to the upper chamber, and 500  $\mu\text{l}$  of negative control medium (EBM-2 with 0.1% HSA and 0.2% antibiotics), positive control medium [10% foetal calf serum (FCS)] or GASC-CM was added to the bottom chamber. After 6 h, the cells that had migrated to the underside of the insert membrane were stained and counted with a computerized image-analysis system, as described above.

#### ***Proliferation assay***

HUVECs ( $1 \times 10^4$  cells/cm $^2$ ) were plated in 96-well plates. They were incubated for 48 h, after which, the culture medium was replaced with 100  $\mu\text{l}$  of negative control medium (EBM-2 supplemented with 0.1% HSA and 0.2% antibiotics), positive control medium (EGM-2) or GASC-CM. The plate was incubated for 72 h. The medium was then removed from the wells and the plate was stored at -80°C until the assay was carried out. Cell survival was estimated with the CyQUANT<sup>®</sup> cell proliferation assay kit, according to the manufacturer's instructions (Fisher Scientific, Illkirch, France). Sample fluorescence was measured with a microplate reader (Fluoroskan Ascent FL, Labsystem, Cergy-Pontoise, France). The fluorescence of HUVECs incubated with the negative control medium was considered to correspond to 100% survival.

#### ***Endothelial tubule formation***

HUVECs ( $5 \times 10^4$  cells/cm $^2$ ) were used to seed 96-well plates coated with Matrigel basement membrane matrix (50  $\mu\text{l}$ /well, BD Biosciences), and were incubated for 6 h in EBM-2 negative control medium, EGM-2 positive control medium or GASC-CM. The length of the endothelial tubule in each field was quantified with Image J software. Data are expressed as means  $\pm$  SEM.

#### **Statistical analysis**

Results are expressed as means  $\pm$  SEM. The Kruskal-Wallis test was used for statistical analyses. Differences were considered significant if  $P < 0.05$ .

## Results

### Gene expression profiles identify two subgroups of GASCs derived from GB

We performed an unsupervised hierarchical clustering analysis of group samples according to their transcriptomic profile (4122 selected probes with an SD  $\geq 0.5$ ). The results of the clustering analysis are presented in the dendrogram in Figure 1a. We observed that the samples are clustered into two main groups: group A, corresponding to four GASC samples and three control stromal cell samples derived from two patients with epilepsy and one patient with an epidermoid cyst, and group B, corresponding to 10 GASC samples and two control stromal cell samples derived from a patient with meningioma and a patient with craniopharyngioma (Figure 1a). Genome-wide methylation profiling gave the same clustering pattern (Figure 1b). Given the heterogeneity of the control stromal cells, we decided to limit our comparisons to group A GASCs (GASC-A) and group B GASCs (GASC-B) in this study.

### Genes differentially expressed between GASC-A and GASC-B

We found that 895 (713 genes) of the 4122 probes selected were differentially expressed between GASC-A and GASC-B: 422 probes (339 genes) were overexpressed and 473 probes (374 genes) were underexpressed in GASC-B (Supplementary Table 2). Hierarchical cluster analysis of the 895 differentially expressed probes clustered GASC samples into GASC-A and GASC-B groups, as in the unsupervised cluster analysis (data not shown). Functional annotation of the differentially expressed genes (NIH-David software) showed enrichment in several Gene Ontology biological processes (Fisher's exact test): cell division, nervous system development, blood vessel development, inflammatory response, epidermal growth factor receptor signaling pathway, cell motion and muscle system processes (Table 1).

We found that 80 of the 339 (24%) overexpressed genes were hypomethylated in GASC-B and 85 of the 374 (23%) underexpressed genes were hypermethylated in GASC-B (Supplementary Table 2). The differentially methylated genes corresponding to the biological term enrichments described above are indicated in Table 1.

### Validation of transcriptomic data for the selected genes

The differential expression of six genes was confirmed by flow cytometry analyses: GASC-B overexpressed the VASP, nestin, THBS1 and CSPG4/NG2 genes and underexpressed the EGFR and ICAM1 genes (Figure 2). We also found that the expression of other myofibroblast- or CAF-associated markers, including  $\alpha$ SMA, PDGFR $\beta$ /CD140b and S100A4/FSP1, was stronger in GASC-B than in GASC-A (Figure 2). These markers were previously shown to be more strongly expressed in GASCs than in control stromal cells [7].

### **Tumor-promoting properties of the two subgroups of GASCs**

We investigated whether the two subtypes of GASCs identified by transcriptome analysis were associated with different tumor-promoting properties, such as invasion and proliferation, using the aneuploid A172 GB cell line. GASC-CM resulted in a greater invasion capacity of A172 cells than culture in the positive control medium (10% HABS) (Figure 3a). No significant difference was observed between the two subgroups of GASCs. No invasion by A172 cells was observed in the presence of the negative control medium (data not shown). The addition of GASC-B to the aneuploid A172 cell line induced an increase in tumor cell proliferation, which was significantly stronger than after the addition of GASC-A (Figure 3b). This result was validated *in vivo*, with the diploid tumorigenic U87MG cell line. The subcutaneous injection into nude mice of GASC-B together with the U87MG cell line resulted in a significantly higher tumor volume induction than the injection of U87MG cells, either alone or in together with GASC-A (Figure 3c).

### **Endothelium-promoting abilities of the two subgroups of GASCs**

We assessed the effect of the two subgroups of GASCs on the migration, proliferation and tubule formation of endothelial cells (Figure 4). We found that both subgroups of GASCs induced slightly higher levels of endothelial cell migration and proliferation than the negative control medium (Figure 4a and 4b). No significant difference was observed between the two subgroups of GASCs. In tubule formation assays, GASC-B resulted in significantly longer tubules ( $175.4 \pm 2.1 \mu\text{m}$ ) than GASC-A ( $151.7 \pm 4.6 \mu\text{m}$ ) and the negative control medium ( $158.7 \pm 4.9 \mu\text{m}$ ) (Figure 4c and 4d).

## **Discussion**

In this study, we identified two subtypes of GASCs in the histologically normal surgical margins of GB patients: GASC-A and GASC-B. The genes differentially expressed between the two subtypes were significantly associated with cell division, blood vessel development and muscle system processes. The GASC-B subtype, corresponding to 71% of the GASC samples analyzed, displayed the characteristics of GASCs described in our previous studies [7]. This subtype had a myofibroblast phenotype and procarcinogenic properties. In particular, unlike the GASC-A subtype, it promoted GB cell growth *in vitro* and *in vivo* and increased the tube length of HUVECs, suggesting that it also had angiogenic properties. The GASC-B subtype did not appear to be specific to the GB microenvironment, as its transcriptome closely resembled those of control stromal cells derived from meningioma and craniopharyngioma. These CNS diseases are considered to display benign biological behavior, but they may present an infiltrative pattern and recur more frequently than other benign tumors [11, 12].

The cells of the GASC-B subtype overexpressed several markers, such as CSPG4/NG2, a transmembrane chondroitin sulfate, CD146/MCAM, a cell adhesion molecule, and nestin, a neural stem cell marker that we previously showed to be more strongly expressed in GASCs than in control stromal cells [7]. These molecules have been shown to be attractive potential biomarkers of cancer prognosis. For example, CSPG4/NG2 has been proposed as a prognostic marker for breast cancers [13], head and neck squamous cell carcinomas (HNSCC) [14] and gliomas [15, 16]. The expression of nestin has been described in tumor and peritumor areas of GB, independently of the presence of neoplastic cells [17, 18]. Nestin expression has been shown to increase with malignancy grade, and high levels of nestin are associated with poor survival [19, 20]. CD146 is abnormally expressed in various tumors and is closely associated with tumor progression [21, 22]. CSPG4/NG2, nestin and CD46 are also potentially attractive targets for cancer treatment [21, 23, 24].

In this study, genome-wide methylation profiling and gene expression profiling gave the same clustering pattern, suggesting that the GASC-B phenotype may result from DNA methylation. Several studies have highlighted the importance of this epigenetic mechanism in the regulation of myofibroblast differentiation [25] and in the maintenance of cancer-associated fibroblast properties [26–29]. The genes differentially methylated between GASC-A and GASC-B included CSPG4/NG2 and CD146, which were hypomethylated in GASC-B, resulting in their overexpression. Changes in the expression of CSPG4/NG2 due to hypomethylation have already been reported for the stroma of human colon carcinoma [30] and in HNSCC [14]. Conversely, ICAM-1 and EGFR were found to be hypermethylated in GASC-B, and this hypermethylation was associated with the underexpression of these genes. ICAM1 silencing by epigenetic regulation has been described in tumor endothelial cells, rendering these cells unresponsive to inflammatory activation [31]. EGFR hypermethylation has been described in a subset of tumors, including GB, breast, colon and lung cancers [32, 33], and may play a role in determining the efficacy of anti-EGFR treatments [33, 34]. In addition to DNA methylation, other mechanisms involved in myofibroblast differentiation, including Wnt, Notch and hedgehog signaling, TGF- $\beta$  and other types of epigenetic regulation, such as histone acetylation and/or small interfering RNAs [25], may induce the GASC-B phenotype.

Our findings indicate that two extratumoral microenvironments can be encountered in GB patients: an extratumoral microenvironment containing GASCs with procarcinogenic properties and another containing GASCs without such properties. In accordance with our findings, Roman-Pérez *et al.*, (2012) [35] reported the presence of two different subtypes of extratumoral microenvironment influencing the aggressiveness and outcome of human breast cancers. Furthermore, in 2013, Al Rakan *et al.* [36] carried out molecular and cellular

characterizations of breast stromal fibroblasts (TCFs) from negative surgical margins. TCFs closely resemble GASCs in terms of their carcinogenic properties and patient-to-patient variability.

All these data indicate that the tumor microenvironment present after resection may play a determinant role in local recurrence. Consistent with this possibility, several studies have highlighted the importance of surgical margin status for determining the likelihood of local relapse [3, 37]. Pirrotte *et al.* (2009) [38] reported longer survival in patients undergoing complete resection of the area of increased tracer uptake on PET, whereas complete resection of the gadolinium-enhanced MR-delineated area did not affect survival, suggesting that metabolic PET may be a more useful presurgical imaging technique. Intraoperative tumor identification in fluorescence-guided surgery with 5-aminolevulinic acid (ALA) is also an emerging technique that increases the rate of complete resections and extends survival [39, 40]. In this era of personalized therapy, the characterization of tumor cells and the status of GASCs located in GB surgical margins should be taken into account, to improve the efficacy of treatment and the prevention of recurrence.

**Conflict of interest:** We have no potential conflicts of interest to declare.

## References

1. Stupp R, Mason WP, Van den Bent MJ, *et al.* (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352:987–996
2. Stupp R, Hegi ME, Mason WP, *et al.* (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10:459–466
3. Petrecca K, Guiot M-C, Panet-Raymond V, Souhami L (2013) Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. *J Neurooncol* 111:19–23
4. Glas M, Rath BH, Simon M, *et al.* (2010) Residual tumor cells are unique cellular targets in glioblastoma. *Ann Neurol* 68:264–269
5. Piccirillo SG, Dietz S, Madhu B, Griffiths J, Price SJ, Collins VP, Watts C (2012) Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. *Br J Cancer* 107:462–8
6. Polanska UM, Orimo A (2013) Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. *J Cell Physiol* 228:1651–7
7. Clavreul A, Guette C, Faguer R, *et al.* (2014) Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. *J Pathol* 233:74–88
8. Clavreul A, Etcheverry A, Chassevent A, *et al.* (2012) Isolation of a new cell population in the glioblastoma microenvironment. *Journal Neurooncol* 106:493–504
9. Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. *Cytometry* 3:323–327
10. Clavreul A, Jean I, Preisser L, Chassevent A, Sapin A, Michalak S, Menei P (2009) Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy. *In vitro Cell Dev Biol Anim* 45:500–511
11. Prieto R, Pascual JM, Subhi-Issa I, Jorquera M, Yus M, Martínez R Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence. *World Neurosurg* 79:733–49

12. Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG (2011) Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg 25:707–13
13. Hsu NC, Nien P-Y, Yokoyama KK, Chu P-Y, Hou M-F (2013) High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer. Biochem Biophys Res Commun 441:514–8
14. Warta R, Herold-Mende C, Chaisaingmongkol J, *et al.* (2014) Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients. Int J Cancer. doi: 10.1002/ijc.28906
15. Svendsen A, Verhoeff JJC, Immervoll H, *et al.* (2011) Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 122:495–510
16. Chekenya M, Pilkington GJ (2002) NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours. J Neurocytol 31:507–21
17. Mangiola A, Lama G, Giannitelli C, *et al.* (2007) Stem cell marker nestin and c-Jun NH<sub>2</sub>-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 13:6970–7
18. Sica G, Lama G, Anile C, Geloso MC, La Torre G, De Bonis P, Maira G, Lauriola L, Jhanwar-Uniyal M, Mangiola A (2011) Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int J Oncol 38:41–9
19. Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW (2013) What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol 6:334–48
20. Hatanpaa KJ, Hu T, Vemireddy V, *et al* (2014) High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. J Neurooncol 117:183–9
21. Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330:150–62
22. Kapoor S (2013) CD146 expression and its close relationship to tumor progression in systemic malignancies besides gall bladder carcinomas. Tumour Biol 34:1273–4
23. Wang J, Svendsen A, Kmiecik J, *et al.* (2011) Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PloS One 6:e23062

24. Matsuda Y, Hagio M, Ishiwata T (2013) Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. *World J Gastroenterol* 19:42–8
25. Hu B, Phan SH (2013) Myofibroblasts. *Curr Opin Rheumatol* 25:71–7
26. Hu M, Yao J, Cai L, Bachman KE, Van den Brûle F, Velculescu V, Polyak K (2005) Distinct epigenetic changes in the stromal cells of breast cancers. *Nature Genet* 37:899–905
27. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG (2006) Gene promoter methylation in prostate tumor-associated stromal cells. *J Ntl Cancer Inst* 98:255–61
28. Jiang L, Gonda TA, Gamble M V, et al. (2008) Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. *Cancer Res* 68:9900–8
29. Tyan S-W, Hsu C-H, Peng K-L, Chen C-C, Kuo W-H, Lee EY-HP, Shew J-Y, Chang K-J, Juan L-J, Lee W-H (2012) Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. *PloS One* 7:e35128
30. Adany R, Heimer R, Caterson B, Sorrell JM, Iozzo R V (1990) Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. *J Biol Chem* 265:11389–96
31. Hellebrekers DMEI, Castermans K, Viré E, et al. (2006) Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. *Cancer Res* 66:10770–7
32. Gömöri E, Pál J, Kovács B, Dóczsi T (2012) Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. *Diagn Pathol* 7:8
33. Montero AJ, Díaz-Montero CM, Mao L, Youssef EM, Estecio M, Shen L, Issa J-PJ (2006) Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. *Cancer Biol Ther* 5:1494–501
34. Scartozzi M, Bearzi I, Mandolesi A, et al. (2011) Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. *Br J Cancer* 104:1786–90
35. Román-Pérez E, Casbas-Hernández P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA (2012) Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. *Breast Cancer Res* 14:R51
36. Al-Rakan MA, Colak D, Hendrayani S-F, Al-Bakheet A, Al-Mohanna FH, Kaya N, Al-Malik O, Aboussekha A (2013) Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic. *J Pathol* 231:457–65

37. De Bonis P, Anile C, Pompucci A, Fiorentino A, Balducci M, Chiesa S, Lauriola L, Maira G, Mangiola A (2013) The influence of surgery on recurrence pattern of glioblastoma. *Clini Neurol Neurosurg* 115:37–43
38. Pirotte BJM, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. *Neurosurgery* 64:471–81
39. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 7:392–401
40. Aldave G, Tejada S, Pay E, Marigil M, Bejarano B, Idoate MA, Díez-Valle R (2013) Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. *Neurosurgery* 72:915–20

## **Acknowledgments**

We thank Abderrahmane Hamlat and Véronique Quillien (CHU, Rennes) for providing control and tumor samples. We also thank Pierre Legras and Jérôme Roux (Service Commun d'Animalerie Hospitalo-Universitaire, Angers), Catherine Guillet (Paltform PACeM, Angers), and the Cancéropole Grand Ouest for allowing us to use their facilities. We thank Alex Edelman and Associates for correcting the English language of the manuscript.

## **Supplementary material**

Supplementary methods: Description of RNA extraction and gene expression profiling and methylation analysis

Supplementary Table 1: Characteristics of the GASC and control stromal cells used in this study. GBO: GB with an oligodendroglial component.

Supplementary Table 2: Probes differentially expressed between GASC-A and GASC-B.

## Figure legends

Figure 1: Hierarchical clustering dendrograms showing gene expression (a) and DNA methylation (b) data from GASCs and control stromal cells. In the dendrogram, the samples or groups (clusters) of samples with similar expression patterns are linked by branches. The vertical axis of the dendrogram represents the distance (dissimilarity) between samples or clusters of samples. The length of the each branch is correlated with size of the difference between the samples it connects. Two main clusters of samples are observed: group A, corresponding to four GASC samples and three control stromal cell samples derived from two patients with epilepsy and one patient with an epidermoid cyst, and group B, corresponding to 10 GASC samples and two control stromal cell samples derived from a patient with meningioma and a patient with craniopharyngioma.






Figure 2: Phenotypic analysis by flow cytometry of GASC-A ( $n = 4$ ) and GASC-B ( $n = 4$ ). GASCs were immunostained with antibodies against CAF-associated markers ( $\alpha$ SMA, CD140b, S100A4, CD146 and CSPG4), nestin, THBS1, VASP, EGFR and ICAM1. Results are expressed as means  $\pm$  SEM of the fold-change ratio of the geometric mean marker-positive/geometric mean isotype control-positive cells and as means  $\pm$  SEM of the difference between marker- and isotype control-positive cells (\*,  $P < 0.05$  between GASC-A and GASC-B).



**Figure 3:** (a) HABS or CM from GASC-A and GASC-B was added to the lower compartments of 24-well plates. A172 cells ( $5 \times 10^4$ ) were used to seed the Transwell inserts and the plates were incubated for 6 h. The percentage cells invading the lower compartment is presented (means  $\pm$  SEM; \*  $P < 0.05$  versus HABS). (b) Direct coculture assay of GASC-A or GASC-B with the aneuploid glioma cell line A172. Bar graphs show means  $\pm$  SEM of the PI fold-change between A172 cells cultured alone and A172 cells cocultured with GASCs (\*,  $P = 0.001$  between GASC-A and GASC-B). (c) U87MG cells were injected alone ( $n = 7$ ) or co-injected with GASC-A ( $n = 5$ ) or GASC-B ( $n = 4$ ) subcutaneously into nude mice. Tumor volume is plotted for the days indicated, as the median  $\pm$  SEM (\*,  $P = 0.008$ , versus U87MG alone).



**Figure 4:** (a) EBM-2, FCS or CM from GASC-A and GASC-B was added to the lower compartments of 24-well plates. HUVECs ( $2.5 \times 10^4$ ) were used to seed Transwell inserts and the plates were incubated for 6 h. The percentage of cells migrating is presented (means  $\pm$  SEM; \*  $P < 0.05$  versus EBM-2). (b) Effect of GASCs on the survival of HUVECs. The cells were incubated for 3 days with EBM-2, EGM-2 or CM from GASC-A or GASC-B. The percentage of cells surviving is presented (means  $\pm$  SEM; \*  $P < 0.05$  versus EBM-2). (c) and (d) Effect of GASCs on tube length. (c) Phase-contrast micrographs of HUVEC tube formation on Matrigel. HUVECs were used to seed Matrigel and were incubated at 37°C for 6 h in EBM-2, EGM-2 or CM from GASC-A or GASC-B (scale bar = 100  $\mu$ m). (d) Tube length was used to quantify angiogenesis. Results are means  $\pm$  SEM (\*  $P = 0.049$  versus EBM-2 or CM from GASC-A).




Table 1: GO biological process enrichment of the genes differentially expressed between GASC-A and GASC-B. Genes overexpressed in GASC-B are shown in bold. The remaining genes were underexpressed in GASC-B. Genes highlighted in gray correspond to genes overexpressed and hypomethylated in GASC-B or underexpressed and hypermethylated in GASC-B.

GO:0008150_biological_process	P-value	Genes
GO:0051301_cell division	$3.56 \cdot 10^{-6}$	CABLES1, <b>C13ORF34</b> , C14ORF106, CCNE2, CDK6, CDKN2A, <b>CENPH</b> , <b>CENPJ</b> , CKS1B, <b>ESPL1</b> , FBXO5, HAUS8, HELLS, KIF20B, KNTC1, <b>LIG1</b> , <b>MAD2L1</b> , MCM5, <b>NCAPD2</b> , NCAPD3, NCAPG2, NEK1, <b>NUF2</b> , PARD3, PTTG1, PTTG2, RACGAP1, <b>SKA3</b> , SMC2, <b>SMC4</b> , ZWINT
GO:0007399_nervous system development	$4.05 \cdot 10^{-4}$	APOE, ARNT2, BAI2, BAIAP2, <b>BEX1</b> , C17ORF28, C1S, CABLES1, <b>CDK5R1</b> , CDK6, CDKN1C, CLDN1, CLU, CXCL1, DCLK1, <b>DLC1</b> , DOK5, <b>EFHD1</b> , EFNB1, EGFR, EPOR, FEZ1, FGF5, <b>GBX2</b> , GFRA1, <b>HEY1</b> , INA, KCNMA1, L1CAM, LMO4, MAFB, <b>MEF2C</b> , MSX1, NEFM, NES, NRGN, NTRK2, PARD3, PBX1, PHGDH, PLXNB1, PTK2B, PTN, RACGAP1, RCAN2, RELN, <b>RGS9</b> , RTN1, RUNX3, <b>SEMA5B</b> , SEPP1, SERPINE2, SERPINF1, <b>SLTRK4</b> , SMAD1, <b>TBX3</b> , TIAM1, TIMP3, TRIM3, UCHL1, <b>VASP</b> , VLDR, XRCC2, ZEB1, ZIC5
GO:0001568_blood vessel development	$7.38 \cdot 10^{-5}$	ARHGAP22, APOE, CCBE1, <b>CSPG4</b> , EREG, FOXO1, <b>GBX2</b> , <b>GJA4</b> , <b>GJC1</b> , LAMA4, LMO2, LOX, NTRK2, PDGFA, PLCD3, PLXDC1, <b>PLXND1</b> , PTK2B, RECK, SEMA3C, <b>TBX3</b> , TGM2, THBS1, TIPARP
GO:0006954_inflammatory response	0.026	AOC3, C1R, C1RL, C1S, C2, C4B, CD14, CD55, CDO1, CFB, CFD, CLU, CXCL1, CYBA, IL17B, IL17D, IL20RB, NUPR1, S1PR3, SMAD1, THBS1
GO:0007173_epidermal growth factor receptor signaling pathway	0.021	EGFR, EREG, HBEGF, PLCE1, PTK2B
GO:0051270_regulation of cell motion	0.003	APOE, <b>DLC1</b> , EGFR, ENPP2, <b>HBEGF</b> , ICAM1, IGFBP3, IGFBP5, LAMA4, <b>MYLK2</b> , PARD3, PDGFA, PTK2B, PTPRU, SERPINE2, <b>THBS1</b> , TRIB1
GO:0003012_muscle system process	0.029	CYBA, GAA, <b>GJC1</b> , GUCY1A3, KCNMA1, MYH11, <b>MYLK2</b> , <b>MYOM1</b> , SCN5A, SLMAP, SMTN, TNNT2, VIPR1

